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Abstract
Background: Depression is one of the most common psychiatric disorders in people living with HIV (PLHIV).
Depression has a negative impact on both mental and physical health and is mainly associated with suboptimal
HIV treatment outcomes. To encourage successful aging and the achievement of the 3 × 90 objectives in older
PLHIV, the psychological domain must not be neglected. In this context and as data are scarce in West Africa, this
study aimed to evaluate the prevalence and the factors associated with severe depressive symptoms in older PLHIV
living in this region of the world.
Methods: Data from PLHIV aged ≥50 years and on ART since ≥6 months were collected in three clinics (two in
Côte d’Ivoire, one in Senegal) participating in the West Africa International epidemiological Databases to Evaluate
AIDS (IeDEA) collaboration. The severity of depressive symptoms was measured using the Center for
Epidemiological Studies Depression scale (CES-D), and associated factors were identified using logistic regressions.
Results: The median age of the 334 PLHIV included in the study was 56.7 (53.5–61.1), 57.8% were female, and
87.1% had an undetectable viral load. The prevalence of severe depressive symptoms was 17.9% [95% Confidence
Interval (95% CI): 13.8–22.0]. PLHIV with severe depressive symptoms were more likely to be unemployed (adjusted
Odd Ratio (aOR) = 2.8; 95% CI: 1.4–5.7), and to be current or former tobacco smokers (aOR = 2.6; 95% CI: 1.3–5.4) but
were less likely to be overweight or obese (aOR = 0.4; 95% CI: 0.2–0.8).
Conclusions: The prevalence of severe depressive symptoms is high among older PLHIV living in West Africa.
Unemployed PLHIV and tobacco smokers should be seen as vulnerable and in need of additional support. Further
studies are needed to describe in more details the reality of the aging experience for PLHIV living in SSA. The
integration of screening and management of depression in the standard of care of PLHIV is crucial.
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Background
During the two last decades, a dramatic positive change
has been observed worldwide in the demographics of
people living with HIV (PLHIV) [1]. Increased access
and use of HIV medical services and the improvement
in antiretroviral therapy (ART) access are the two main
reasons for this change. HIV infection is now considered
a chronic disease in most settings, including in sub-Saharan
Africa (SSA) [1]. PLHIV have a lifespan comparable to that
observed in the general population and are getting older.
With aging, PLHIV experience more complications in
the physiological domain. The compromised immune
system with the involution of the thymus, ART side
effects, and polypharmacy are a pathway to explain these
complications [2]. Older patients receiving ART are at
an increased risk of age-associated non-communicable
comorbidities (AANCC), like cardiovascular diseases,
renal diseases, diabetes, cancers, osteoporosis, and
neuropsychological impairment [3, 4]. Among these
AANCC, insufficient attention has been paid to mental
health issues. However, to facilitate successful aging in
the context of chronic diseases, such as HIV disease, the
psychological and social domains must not be neglected
[5]. In Young et al. model [5], psychological and social
domains could be a way to compensate for physiological
limitations (i.e., multiple chronic conditions) and allow,
even in the context of disease and disability, to experi-
ence a good quality of life.
In PLHIV on ART, depression is among the most
common psychiatric disorders [6] and has a high preva-
lence. In SSA, a recent meta-analysis reported a pooled
prevalence of 13% for major depressive disorder and
between 14 to 32% for severe depressive symptoms in
those patients [7]. The consequences of depression on
linkage to care and HIV response are crucial. First,
depression has been shown to predict non-adherence to
ART [8–11]. In South Africa, one study reported that,
compared to adherent patients, non-adherent patients
had a 3-fold higher risk of presenting moderate to severe
depressive symptoms [12]. Second, depression is associ-
ated with poor health status overall [13–16], and poor
HIV outcomes [17]: low CD4 progression [18–20], but
also with faster progression to AIDS and increased mor-
tality [6, 21]. As in the general population, depression is
highly associated with suicide [22]. Third, depression
impacts the quality of life in PLHIV [6]. Its occurrence
leads to alteration of economic productivity, unemploy-
ment [20, 23], social isolation, stigmatization [24],
disability [25], and also high sexual risk behaviors [26].
In western countries, untreated depression in PLHIV has
also been related to increased cognitive complaints and
negative consequences in multiple aspects of quality of
life [27–29]. In addition to aging-related problems, these
medical and psychological factors may be exacerbated in
older PLHIV [30]. In this context, depression could
seriously compromise ART outcomes at individual and
population levels and the achievement of the 3 × 90
objectives.
Despite depression substantially increasing over the
past few years, data to document this significant
dimension of the HIV epidemic in older PLHIV in SSA
are scarce. While SSA is the part of the world that is
the most affected by HIV/AIDS [6], depression often
remains under-diagnosed [6, 31]. As depression in
PLHIV emerges as a public health issue, the risk of a
burden on the healthcare system and human resources
is significant. Evaluating the prevalence of severe de-
pressive symptoms and identifying associated factors
will provide insights for clinical interventions. In this
context, the present study aims to describe the preva-
lence and identify factors associated with severe
depressive symptoms in PLHIV aged 50 years and
above living in West Africa.
Methods
Study design
This study is a part of an ancillary study project within
the West Africa network of the International epidemio-
logical Databases to Evaluate AIDS (IeDEA) of the US
National Institutes of Health (https://www.iedea.org/re
gions/west-africa/) [32]. This study was conducted in
two different countries, in three urban clinics with a
large caseload of PLHIV and selected by convenience:
the infectious and tropical disease department of the
Treichville University Hospital (Abidjan, Côte d'Ivoire),
the public referral clinic (CePReF) in Yopougon Attié
Hospital (Abidjan, Côte d’Ivoire) and the infectious and
tropical disease department of the Fann University Hos-
pital (Dakar, Senegal). The inclusion period of the study
occurred between February 2016 to November 2017. We
performed a cross-sectional analysis based on the base-
line data of a 2-year longitudinal study evaluating differ-
ent aspects of aging with HIV (cognition, physical
function, and frailty), and the presence of severe depres-
sive symptoms with a follow-up still ongoing.
Study population
Patients were recruited at the time of their usual HIV
follow-up visit. Patients were eligible if they were living
with type-1 HIV, 50 years old or older, and on ART for
at least six months. We excluded patients having a
psychiatric illness (including being under psychotropic
treatment), a history of opportunistic cerebral infection,
a neurological pathology (history of stroke or Parkinson
disease), a current disabling opportunistic infection,
meningitis, a sensitivo-motor paralysis, or cancer under
treatment or respiratory or cardiac insufficiency.
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Severity of depressive symptoms
The severity of depressive symptoms was evaluated with
the Center for Epidemiological Studies Depression scale
(CES-D), a 20-item self-report scale assessing the occur-
rence of depressive symptoms during the past week
using a 4-point Likert scale [33]. Due to variability in
patients’ literacy level, each item was read aloud by a
trained doctor or nurse. A translation of items in the na-
tional language other than French was used if necessary.
Although CES-D does not provide a clinical diagnosis of
depression, this scale has been reported as suitable in
the context of epidemiological studies targeting French-
speaking patients [34]. Even though this scale was not
validated specifically in older PLHIV in West Africa, a
recent meta-analysis reported a high pooled sensitivity
and specificity for the CES-D, based on three African
studies (Uganda, Zambia, South Africa) for threshold
ranges between 16 and 22 (sensitivity 82% [95% CI, 73–
87], specificity 73% [95% CI, 63–80]) [35]. It was also
validated in Uganda, with scores > 16 having a good
sensibility and specificity in predicting major depression
disorders [36]. For the analyses, a total score ≥ 17 for
men and ≥ 23 for women was used to define severe
depressive symptoms [37].
Other covariates
Data were collected through essential questions and med-
ical examination. Patients’ sociodemographic characteristics
as age, gender, level of education, marital status, and em-
ployment status were recorded.
Concerning HIV medical data, the initial clinical stage
was defined using the Centers for Disease Control and
Prevention (CDC) definition (A, B, or C). Baseline Nadir
CD4 and more recent CD4 were presented in two
categories (≤200 vs > 200 cells/μl, and < 500 vs ≥500
cells/μl, respectively). The composition of the initial and
current ART treatment was presented through a cat-
egorical variable (TDF/3TC/EFV vs other combination).
The duration of HIV disease was calculated as the delay
in months between the first positive serology date and
the study’s inclusion date. Adherence to ART was
defined as the percentage of tablets the patient declared
to take over 7 days (in comparison to the prescribed
total number of tablets over this period).
Substance use was evaluated through basic questions
for tobacco and drugs (current, former, or never).
Alcohol consumption was evaluated with the AUDIT-C.
A score ≥ 3 for women or ≥ 4 for men was considered as
hazardous drinking.
The Body Mass Index (BMI) was calculated as weight in
kilograms/height in meters squared and considered in two
categories: low or normal BMI (low when < 18 kg/m2, nor-
mal between 18 to 24 kg/m2) and high when ≥25 kg/m2.
Patients were also asked if they had ever been diagnosed
with these comorbidities: hypertension, diabetes, hyperlip-
idemia, C or B hepatitis, tuberculosis, migraine, arthrosis,
or other. A variable “comorbidities” was created with three
categories: absence, only one, or more than one
comorbidity. History of trauma and neurologic diseases
was also documented.
Measures of functional status
Activities of the daily living (ADL) [38] and Instrumental
activities with daily living (IADL) [39] scales were used
to evaluate the autonomy of the patients. The final ADL
and IADL scores range from 0 to 6 and 0 to 4, respect-
ively (0, indicating the lowest degree of autonomy).
Statistical analysis
The study sample characteristics were described using
median and interquartile range (IQR) for continuous
variables, numbers, and proportions for categorical
variables.
In order to describe the five most reported depressive
symptoms among depressed PLHIV, we used the factorial
structure described by Sheehan et al., [40] grouping the
items 1, 2, 5, 7, 11, 13 and 20 as somatic symptoms, the
items 3, 6, 14, 17 et 18 as depressive affects, the items 4, 8,
12 and 16 as negative affects, and the items 9, 10, 15 et 19
as interpersonal deficit. For this analysis, each item was
recoded in two categories: the significant presence of the
symptoms (≥3 days) or no (≤2 days). As the expression of
depression could be different between females and males,
we identified which symptoms were significantly most
reported according to gender, using Chi-2 tests.
The prevalence of severe depressive symptoms was
reported. Then, factors associated with the presence of
severe depressive symptoms were evaluated using logistic
regression analyses. Before conducting logistic regression
analyses, a multivariable Random Forest imputation of
missing data was performed. As no significant difference
was observed between the two databases (with and with-
out missing data), we used the database with imputed
missing data for these analyses. In the multivariable re-
gression model, we included all variables associated with
the dependent variable with a p-value≤0.2 in univariable
analyses. The “inclusion centers” variable was included as
a cofounder in each model. Unbalanced variables (85%/
15%) were excluded from the multivariable analyses. The
final model was obtained with a backward selection, and
we considered significant associations at p < 0.05. The
goodness of fit of the final model was evaluated with the
Hosmer-Lemeshow test (p > 0.05). Statistical analyses were
computed using R software.
Ethical consideration
Ethical clearance was obtained from the national ethics
committee of each participating country (Senegal: Conseil
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National d’Ethique de la Recherche en Santé (CNERS);
Côte d’Ivoire: Comité National de l’Ethique et de la
Recherche). All the patients gave their written consent
before being included in the study. Participants’ right to
refuse the participation was kept, and the confidentiality
of the patient was maintained. To have a further assess-
ment on their condition, patients with severe depressive
symptoms were referred to a psychiatrist within the
hospital.
Results
Characteristics of the sample
A total of 334 patients were included in our study. The
median (IQR) age was 56.7 (53.5–61.1) years. Among
them, 34.7% were aged 60 and older (only 11 were aged
≥70), 57.8% were female, and 50.6% had a primary level
of education or less. Almost half of them lived in couple
(46.4%) and were currently employed (53.6%) (Table 1).
A large majority of patients had an undetectable viral
load (87.1%); half of them having CD4 ≥ 500 (50.3%) and
60.8% a Nadir CD4 < 200. The median (Interquartile -
IQR) duration of HIV infection was 108 months (68.9–
141.0). Fourteen percent (14.4%) were on stage C at
ART initiation. Concerning ART treatment, 25 and
52.7% received the standard combination for their initial
and current treatment (according to the national treat-
ment guidelines), respectively. Patients reported high
adherence to ART (94.3%).
Few patients reported substance use (< 8%), except for
tobacco (current/previous) (17.1%).
For other medical issues, 38% were overweight or
obese, 35.3% reported one comorbidity in addition to
their HIV disease, and 22.2% more than one.
In terms of the ADL and IADL instruments, 97.0 and
99.1% of the patients got the maximum score (6 or 4,
respectively).
Prevalence of severe depressive symptoms
The prevalence of severe depressive symptoms was
17.9% [95% Confidence Interval (CI): 13.8–22.0]. Among
PLHIV with severe depressive symptoms (N = 60), 80%
reported somatic symptoms, 73.3% depressive affects,
71.7% negative affects and 40% interpersonal deficit. The
five most reported symptoms (Fig. 1) were: “not enjoying
life” (70%), “being unhappy” (66.7%), “being restless”
(63.3%), “feeling depressed” (58.3%) and “sadness”
(56.7%). Compared to males, females reported more
frequently the following symptoms: “being restless”
(78.6% vs 50%, p = 0.02), “crying spells” (42.9% vs 18.7%,
p = 0.03), “sadness” (71.4% vs 43.7%, p = 0.03) and “not
enjoying life” (82.1% vs 58.4%, p = 0.05). They also
reported more frequently that their life is a failure
(71.4% vs 40.6%, p = 0.02).
Factors associated with severe depressive symptoms
In univariate models (Table 2), having a longer duration
of the disease ≥141 months (OR = 3.2; 95% CI: 1.3–7.6),
being unemployed (OR = 1.9; CI95%: 1.0–3.8), a Nadir
CD4 ≤ 200 (OR = 2.1; CI95%: 1.1–4.2), a detectable viral
load (OR = 3.1; 95% CI: 1.5–6.3) were significantly asso-
ciated with the presence of severe depressive symptoms.
PLHIV with severe depressive symptoms were also more
likely to be current or former tobacco smokers (OR =
2.5; 95% CI: 1.3–4.9) but were less likely to be over-
weight or obese (OR = 0.4; 95% CI: 0.2–0.8).
In the multivariate model, being unemployed (adjusted
OR (aOR) = 2.8; 95% CI: 1.4–5.7), being a current or
former tobacco smokers (aOR = 2.6; 95% CI: 1.3–5.4)
and being overweight or obese (aOR = 0.4; 95% CI: 0.2–
0.8) remained associated with severe depressive symp-
toms (Goodness of Fit: χ2 = 5.4, p = 0.71).
Discussion
In the present study, in a large sample of PLHIV aged
50 years and above, severe depressive symptoms were
observed in almost 18% of the patients. The severity of
depressive symptoms seems to be more related to social
(i.e., having no professional activity) and behavioral (i.e.,
being current or former tobacco) aspects. Unexpectedly,
being overweight or obese seems to be a protective
factor for the occurrence of depressive symptoms.
The prevalence of depressive symptoms is high and
could not be neglected. In the context of the 3 × 90
objectives, screening, and management of mental health
disorders, including depression, has been listed as a
research priority to improve timely diagnosis, ART initi-
ation, retention, and viral suppression [41]. Recent data
have also reported a 24% increased risk of mortality in
older PLHIV who are depressed [42].
Recent publications from western countries reported
variable results for the prevalence of severe depressive
symptoms in older PLHIV. Among PLHIV aged 50 years
or older living in Portugal, 23.9% presented chronic anx-
iety or depression [43]. In PLHIV aged between 56 to 65
living in the United States, the prevalence of severe de-
pressive symptoms was 28.2% [27]. Data from SSA are
scarce, presenting either the prevalence of a diagnosis of
depression in PLHIV aged 50 years old or above or the
age effects on depressive symptoms. In South Africa, the
prevalence of major depressive disorders was 14.8% in
PLHIV aged 50 years old or above on ART [44]. In rural
South Africa, no significant difference was observed
between age groups among PLHIV on ART but with a
small sample size for the oldest (≥50 years) [45]. In other
studies, younger age was associated with the presence of
severe depressive symptoms but including a limited
number of PLHIV aged above 50 years in Cameroun
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Table 1 Characteristics of the study population according to the severity of depressive symptoms
Characteristics No severe depressive symptoms Severe depressive symptoms p* TOTAL
N % N % N %
274 (82.1) 60 (17.9) 334 (100.0)
Socio-demographic data
Age 0.73
50–59 180 (65.7) 38 (63.3) 218 (65.3)
60–69 94 (34.3) 22 (36.7) 116 (34.7)
Gender 0.05
Male 109 (39.8) 32 (53.3) 141 (42.2)
Female 165 (60.2) 28 (46.7) 193 (57.8)
Education level 0.13
No education 81 (29.6) 10 (16.7) 91 (27.2)
Primary school 61 (22.3) 17 (28.3) 78 (23.4)
Secondary school 100 (36.5) 28 (46.7) 128 (38.3)
University & Tertiary Education 32 (11.6) 5 (8.3) 37 (11.1)
Marital Status 0.36
Married/Cohabitating 125 (45.6) 30 (50.0) 155 (46.4)
Widowed 93 (34.0) 14 (23.3) 107 (32.0)
Divorced 20 (7.3) 7 (11.7) 27 (8.1)
Never married 36 (13.1) 9 (15.0) 45 (13.5)
Employment status 0.08
Currently employed 153 (55.8) 26 (43.3) 179 (53.6)
Unemployed 70 (25.5) 22 (36.7) 92 (27.5)
Retired 51 (18.6) 12 (20.0) 63 (18.9)
HIV Clinical data
Clinical disease stage at ART initiation 0.42
A 86 (31.4) 14 (23.3) 100 (29.9)
B 145 (52.9) 37 (61.7) 182 (54.5)
C - AIDS 39 (14.2) 9 (15.0) 48 (14.4)
Unknowm 4 (1.5) . . 4 (1.2)
Duration of infection (months) 0.08
[6–69[ 75 (27.4) 8 (13.3) 83 (24.9)
[69–108[ 69 (25.2) 14 (23.3) 83 (24.9)
[108–141[ 65 (23.7) 16 (26.7) 81 (24.3)
≥ 141 65 (23.7) 22 (36.7) 87 (26.0)
Nadir CD4 0.02
> 200 106 (38.7) 14 (23.3) 120 (35.9)
≤ 200 158 (57.7) 45 (75.0) 203 (60.8)
Missing 10 (3.6) 1 (1.7) 11 (3.3)
Most recent CD4 0.38
≥ 500 141 (51.5) 27 (45.0) 168 (50.3)
< 500 130 (47.4) 32 (53.3) 162 (48.5)
Missing 3 (1.1) 1 (1.7) 4 (1.2)
Detectable Viral load 27 (9.9) 16 (26.7) < 0.001 43 (12.9)
Missing 47 (17.2) 9 (15.0) 56 (16.8)
Initial ART combinaison 0.11
3TC + TDF + EFV 72 (26.3) 10 (16.7) 82 (24.6)
Other 200 (73.0) 50 (83.3) 250 (74.9)
Missing 2 (0.7) . . 2 (0.6)
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Table 1 Characteristics of the study population according to the severity of depressive symptoms (Continued)
Characteristics No severe depressive symptoms Severe depressive symptoms p* TOTAL
N % N % N %
274 (82.1) 60 (17.9) 334 (100.0)
Actual ART combinaison 0.06
3TC + TDF + EFV 151 (55.1) 25 (41.7) 176 (52.7)
Other 123 (44.9) 35 (58.3) 158 (47.3)
Adherence to ART (yes) 261 (95.3) 54 (90.0) 0.06† 315 (94.3)
Substance use
Hazardous drinkers 18 (6.6) 7 (11.7) 0.18 25 (7.5)
Tobacco use (current/former) 39 (14.2) 18 (30.0) 0.004 57 (17.1)
Drug consumption 4 (1.5) 2 (3.3) 0.30† 6 (1.8)
Anthropometric and medical data
Overweight/obesity 114 (41.6) 13 (21.7) 0.004 127 (38.0)
Comorbidities 0.61
None 119 (43.4) 23 (38.3) 142 (42.5)
One 97 (35.4) 21 (35.0) 118 (35.3)
More than one 58 (21.2) 16 (26.7) 74 (22.2)
History of trauma (yes) 18 (6.6) 4 (6.7) 1.0 22 (6.6)
History of neurological disease (yes) 37 (13.5) 11 (18.3) 0.33 48 (14.4)
Inclusion centers 0.31
CePREF, Abidjan 93 (33.9) 15 (25.0) 108 (32.3)
ITDD, Abidjan 140 (51.1) 37 (61.7) 177 (53.0)
ITDD, Dakar 41 (15.0) 8 (13.3) 49 (14.7)
Abbreviations: ART antiretroviral therapy, ITDD infectious and tropical disease department
* p-value associated with Chi-2 test
† p-value associated with Exact Fisher Test
Fig. 1 Frequency of depressive symptoms reported by the patients in the whole sample and according to gender repartition.
*Significant difference between male and female
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Table 2 Factors associated with severe depressive symptoms in the study population
Variables Univariable models Multivariable model
% severe depressive symptomsa OR (95% CI)* p-value aOR (95% CI)* p-value
Age 0.71
50–59 years old 17.4 1
≥ 60 years old 18.9 1.1 (0.6–2.0)
Gender 0.09
Men 22.7 1
Women 14.5 0.6 (0.4–1.1)
Education level
No education 10.9 1
Primary school 21.8 2.2 (0.9–5.2) 0.08
Secondary school 21.9 2.1 (0.9–4.7) 0.07
University & Tertiary Education 13.5 1.1 (0.3–3.6) 0.87
Marital Status
Married/Cohabitating 19.3 1
Widowed 13.1 0.7 (0.3–1.3) 0.23
Divorced 25.9 1.6 (0.6–4.2) 0.33
Never married 20.0 1.0 (0.4–2.3) 0.99
Employment status 0.11 0.01
Currently employed 14.5 1 1
Unemployed 23.9 1.9 (1.0–3.8) 0.04 2.8 (1.4–5.7) 0.003
Retired 19.1 1.3 (0.6–2.8) 0.51 1.2 (0.5–2.6) 0.67
Duration of HIV infection
[6–69[ 9.6 1
[69–108[ 16.7 1.9 (0.8–4.8) 0.17
[108–141[ 19.7 2.3 (0.9–5.8) 0.07
≥ 141 24.4 3.2 (1.3–7.6) 0.01
Clinical disease stage
A 14.0 1
B 19.9 1.3 (0.6–2.7) 0.46
C 18.7 1.2 (0.5–3.2) 0.67
Nadir CD4 < 0.0001
> 200 11.2 1
≤ 200 22.0 2.1 (1.1–4.2)
CD4 0.36
≥ 500 15.9 1
< 500 20.1 1.3 (0.7–2.3)
Viral load 0.002
Undetectable 15.1 1
Detectable 37.2 3.1 (1.5–6.3)
Initial ART combination 0.10
3TC + TDF + EFV 12.2 1
Other 19.8 1.8 (0.9–3.8)
Actual ART combination 0.06
3TC + TDF + EFV 14.2 1
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[46] or only middle-aged PLHIV in East Africa (mean
age: 37.2 years) were included in those studies [14].
Compared to middle-aged PLHIV (median age < 45
years, 200 PLHIV included), and when using also the
CES-D with the same cut-off as in our study, a prevalence
of 18% was observed in Senegal [47]. In Nigeria and South
Africa, using CES-D but with a cut off ≥16, the prevalence
of severe depressive symptoms in middle-aged PLHIV
(mean age < 45 years) on ART for at least six months was
similar or higher (21 to 62%) [23, 48, 49]. In this context,
we cannot conclude that older PLHIV are more likely to
have severe depressive symptoms than younger ones.
However, the lived reality of older PLHIV might be differ-
ent from the one of the youngest.
Indeed, based on western countries’ studies, older
PLHIV had to face different types of problems, including
stigma [50] and specific concerns about disclosure due
to age [51]. They also have some uncertainty about how
aging, HIV, and long-term ART effects could interact
and impact health [51]. The chronic aspect of the dis-
ease status and the increase of potential comorbidities
with age could play an essential role in PLHIV related-
depression, as observed in other chronic diseases [52].
Further studies are needed to better understand the real-
ity of aging experience in PLHIV living in SSA.
Unemployment is commonly associated with depression
or severe depressive symptoms in middle-aged PLHIV
(mean age < 45 years) living in SSA [23, 31, 46, 53]. In
South Africa, it was shown that unemployed PLHIV could
have a 3-fold risk to present severe depressive symptoms
and more than a 2-fold risk to be non-adherent to ART
[23]. Even if we did not document any income informa-
tion, being unemployed is often indirectly related to a lack
of income, and so poverty. Acting as a stressor, low
income could lead to difficulties in supporting health ex-
penses, particularly the one due to other comorbidities,
which are more likely to be numerous when PLHIV are
getting older. Concerning retirement, we did not collect
information about pension, limiting our conclusions.
Prior studies have documented an association between
current cigarette smoking or nicotine dependence and
the presence of severe depressive symptoms in middle-
aged PLHIV living in western countries [54–56] but also
with a diagnosis of major depression in older PLHIV
living in Brazil [57]. As older PLHIV living in SSA are
more likely to be regular smokers, and as tobacco con-
sumption is often under-estimated [58], it is essential to
screen depression in those patients. Even though few
data are available about previous smokers among older
PLHIV, those individuals might also be vulnerable and
should be screened for depression.
The association between BMI and severe depressive
symptoms in PLHIV is not systematically explored and
makes no consensus [25, 59–61]. A low BMI could be
an indirect marker of loss of appetite, one of the most
reported symptoms in HIV related-depression. A low
Table 2 Factors associated with severe depressive symptoms in the study population (Continued)
Variables Univariable models Multivariable model
% severe depressive symptomsa OR (95% CI)* p-value aOR (95% CI)* p-value
Other 22.1 1.7 (0.9–3.1)
Non adherence to ART
(ref.: adherent)
38.5 3.1 (0.9–9.9) 0.06
Alcohol consumption
(ref.: no)b
28.0 1.9 (0.7–4.8) 0.18
Tobacco (current/former) (ref.: no) 31.6 2.5 (1.3–4.9) 0.01 2.6 (1.3–5.4) 0.01
Drug consumption (ref.: no) 33.3 1.9 (0.3–11.0) 0.45
BMI 0.01 0.01
Normal / underweight 22.7 1 1
Overweight/obesity 5.9 0.4 (0.2–0.8) 0.4 (0.2–0.8)
Comorbidities
No 16.2 1
Only one 17.8 1.2 (0.6–2.3) 0.62
More than one 21.6 1.7 (0.8–3.4) 0.18
History of trauma (ref.: no) 18.2 0.9 (0.3–3.1) 0.99
History of neurological disease (ref.: no) 22.9 2.3 (0.9–5.6) 0.07
Abbreviations: aOR adjusted Odd Ratio, ART antiretroviral therapy, BMI Body Mass Index, CI Confident Interval, EFV Efavirenz, OR odd ratio, ref. Reference group,
TDF Tenofovir, 3TC Lamivudine
*results considered as significant (p < 0.05) (bold text)
aCalculated after imputation of missing data
bref.: no: means that the OR is computed taking this category “absence of this medical problem” as the reference group
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BMI could also be a marker of advanced disease, and in
the social representation, HIV infection and mental
illness are also often associated with thinness. Being
overweight or obese could be in some ways protective
against bad mood or stigmatization, but further investi-
gations are needed to depict this point.
As observed in other studies conducted in SSA in
middle-aged PLHIV, no effect of gender was observed
[20, 24, 47]. However, the expression of depressive
symptoms seems to be different in women and men,
which is essential for clinicians to identify depressed
patients.
In regard to HIV clinical data, a longer duration of the
disease and a lower Nadir CD4 are associated in the
univariate model with severe depressive symptoms. The
impact of physical and emotional difficulties on the lived
HIV experience should not be underestimated. In
addition to the actual problem of living with HIV, long-
time survivors might have to face different problems
compared to those diagnosed more recently (i.e., confu-
sion about surviving so far, a mourning of friends or
family members lost to AIDS) [62]. The link with viral
load could not be further investigated in our sample be-
cause of a significant proportion of missing data.
As depression has deleterious effects on PLHIV but is a
modifiable condition, we encourage the screening and the
management of depression in older PLHIV living in SSA.
Promising results from a culturally-sensitive psychothera-
peutic intervention [63] or a group-based counseling
intervention [64] using task-shifting in middle-aged PLHIV
living in SSA have already been reported. As older PLHIV
are less likely to be engaged in behavioral health treatment
for depression than younger PLHIV [65], it is essential to
adapt psychotherapeutic interventions to the older PLHIV
specific needs.
This study’s major strength is the opportunity to de-
scribe the prevalence of severe depressive symptoms in a
large sample of older PLHIV, included in 3 different sites
in West Africa. However, the generalizability of the
results and the comparison with other studies could be
limited as we included PLHIV on ART for at least six
months within hospital-based study sites from urban set-
tings. Second, the presence of depressive symptoms has
been evaluated in the literature with diverse tools with
different psychometric validities, leading to substantial
variability in the measurements [7], hence results may
not be generalizable across tools. Third, considerable
stress related to HIV (i.e., HIV-related stigma, disclosure
concerns, ART, physical changes) are essential determi-
nants of depression and should not be underestimated
even in older PLHIV. Further studies are needed to de-
pict this. Fourth, even high pooled sensitivity and specifi-
city was observed for the CES-D scale in African studies
[35], a full clinical evaluation was not included in our
scientific protocol to validate a major depressive disorder.
As an interviewer-administered approach was used, and
despite the staff’s full training, social-desirability bias
might not be completely avoided. Finally, the cross-
sectional design of the present study cannot provide infor-
mation on the causal direction.
Conclusions
The prevalence of severe depressive symptoms is high
among older PLHIV living in West Africa, representing
a severe problem for the organization of care and
follow-up of PLHIV.
Unemployment and tobacco use were the main factors
associated with severe depressive symptoms. Those pa-
tients should be considered as vulnerable and requiring
additional support. Further studies in older PLHIV are
needed to describe the phenomenon in more details and
to better understand the reality of aging experience in
PLHIV living in SSA. To guarantee the achievement of
the 3 × 90 objectives, and encourage successful aging in
PLHIV in West Africa, efforts are needed to integrate
screening and management of depression in the standard
of care. Finally, psychotherapeutic intervention adapted to
older PLHIV specific needs should be developed.
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